Urinary Diversion/Reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms

Author(s): DeLong J, Tighiouart H, Stoffel J


Purpose:We assessed surgical outcomes for patients intolerant of catheters with secondary progressive multiple sclerosis undergoing urinary diversion/reconstruction for refractory urinary symptoms.

Materials and methods:Patients with secondary progressive multiple sclerosis treated with ileovesicostomy, enterocystoplasty and ileal loop surgeries were reviewed for demographic, operative and postoperative data. All patients had attempted maximal conservative therapy, including catheterization options. Evaluated outcome measures included incidence of postoperative urinary incontinence, urinary tract infections and Clavien grade 3 or higher complications.

Results:A total of 26 patients (22 female) with secondary progressive multiple sclerosis underwent 15 ileovesicostomy, 7 enterocystoplasty and 4 ileal loop procedures. All patients had significant neurological impairment (mean Expanded Disability Status Scale 7), and the most common indications for surgery were chronic urinary tract infection (77%) and refractory incontinence (77%). Maximum preoperative bladder capacity was 185 cc and mean bladder compliance was 5.7 cc/cm H(2)O. After a mean followup of 16 months 63% of patients were continent (p = 0.01) and 58% had no further urinary tract infections (p = 0.03). The type of diversion/reconstruction was not associated with significantly improved continence or urinary tract infection reduction. No new upper tract changes developed in any patients. There were 11 high grade complications, and patients with a preoperative indwelling catheter (HR 5.89, p = 0.024), diabetes (HR 5.60, p = 0.009) and increasing blood loss during surgery (HR 1.09, p = 0.014) were at greatest risk for significant complications.

Conclusions:Patients with secondary progressive multiple sclerosis treated with urinary diversion/reconstruction who cannot tolerate catheters had improved continence and fewer urinary tract infections. However, patients with secondary progressive multiple sclerosis with preoperative indwelling catheters, diabetes, increased body mass index and increasing operative blood loss were at greatest risk for postoperative morbidity.

Similar Articles

A UK consensus on the management of the bladder in multiple sclerosis

Author(s): Fowler CJ, Panicker JN, Drake M, Harris, Harrison SCW, et al.

Disparities in the management of multiple sclerosis-related bladder symptoms

Author(s): MarrieRA, Cutter G, Tyry T, Vollmer T, Campagnolo D

The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines

Author(s): de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B; GENULF

Urinary complications and risk factors in symptomatic multiple sclerosis patients

Author(s): Castel-Lacanal E, Gamé X, Clanet M, Gasq D, De Boissezon X, et al.

The neural control of micturition

Author(s): Fowler CJ, Griffiths D, de Groat WC

Botulinum toxin treatment for bladder dysfunction

Author(s): Santos-Silva A, da Silva CM, Cruz F

Renal deterioration in multiple sclerosis patients with neurovesical dysfunction

Author(s): Fletcher SG, Dillon BE, Gilchrist AS, Haverkorn RM, Yan J, et al.

First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm

Author(s): Amarenco G, Chartier-Kastler E, Denys P, Jean JL, de Seze M et al.

Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis

Author(s): Koldewijn EL, Hommes OR, Lemmens WA, Debruyne FM, van Kerrebroeck PE

Role of cannabinoids in multiple sclerosis

Author(s): Zajicek JP, Apostu VI

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

Author(s): Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

Author(s): Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, et al.

The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review

Author(s): Tubaro A, Puccini F, De Nunzio C, Digesu GA, Elneil S, et al.

Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder

Author(s): Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, et al.

Botulinum toxin therapy for neurogenic detrusor overactivity

Author(s): Smaldone MC1, Ristau BT, Leng WW

Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis

Author(s): Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, et al.

Clinical outcomes of sacral neuromodulation in patients with neurologic conditions

Author(s): Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA

Impact of intermittent catheterization on the quality of life of multiple sclerosis patients

Author(s): Castel-Lacanal E, Gamé X, De Boissezon X, Guillotreau J, Braley-Berthoumieux E, et al.